title: SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.
abstract: BACKGROUND
  This open-label, randomised phase III study was designed to further investigate the clinical activity and safety of SRL172 (killed Mycobacterium vaccae suspension) with chemotherapy in the treatment of non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients were randomised to receive platinum-based chemotherapy, consisting of up to six cycles of MVP (mitomycin, vinblastine and cisplatin or carboplatin) with (210 patients) or without (209 patients) monthly SRL172.
  
  
  RESULTS
  There was no statistical difference between the two groups in overall survival (primary efficacy end point) over the course of the study (median overall survival of 223 days versus 225 days; P = 0.65). However, a higher proportion of patients were alive at the end of the 15-week treatment phase in the chemotherapy plus SRL172 group (90%), than in the chemotherapy alone group (83%) (P = 0.061). At the end of the treatment phase, the response rate was 37% in the combined group and 33% in the chemotherapy alone group. Patients in the chemotherapy alone group had greater deterioration in their Global Health Status score (-14.3) than patients in the chemotherapy plus SRL172 group (-6.6) (P = 0.02).
  
  
  CONCLUSIONS
  In this non-placebo controlled trial, SRL172 when added to standard cancer chemotherapy significantly improved patient quality of life without affecting overall survival times.
authors.affiliation: The Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK. maryo@icr.ac.uk
authors.forename: M E R
authors.initials: ME
authors.lastname: O'Brien
authors.forename: H
authors.initials: H
authors.lastname: Anderson
authors.forename: E
authors.initials: E
authors.lastname: Kaukel
authors.forename: K
authors.initials: K
authors.lastname: O'Byrne
authors.forename: M
authors.initials: M
authors.lastname: Pawlicki
authors.forename: J
authors.initials: J
authors.lastname: Von Pawel
authors.forename: M
authors.initials: M
authors.lastname: Reck
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use; D011788:Quality of Life; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D001428:Bacterial Vaccines; D008937:Mitomycins; C451081:SRL172; D014747:Vinblastine; D002945:Cisplatin